Meet the Little-Known Disruptor Eyeing the 293+% Growth of a Potential $59 Billion Market… (1) (3)

See what FDA approval could mean for little-known MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA).

Latest News

MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA)  Shows its Prescription Pill More Palatable and Potent Than Pot.

The Canna-bi-diol (C-B-D) Market Soaring Towards a Staggering 293% Growth by 2032… (2)

chart-1

The Canna-bi-diol (C-B-D) market, fueled by its remarkable therapeutic potential, is on the brink of an explosive growth trajectory. With the increasing prevalence of chronic diseases and the progressive legalization of C-B-D in various regions, the C-B-D market is set to skyrocket.
According to projections, the market size, valued at USD $15.6 billion in 2021, is primed to undergo a momentous transformation, reaching an astonishing USD $59.43 billion by 2030. This exponential surge is expected to manifest through a robust compound annual growth rate (CAGR) of 18.2% during the forecast period spanning from 2022 to 2030. (3) Image Source (2)

Unraveling the Canna-bi-diol (C-B-D) Market Phenomenon (3)

The driving forces behind this unprecedented growth in the C-B-D market are multifaceted. First and foremost, the escalating incidence of chronic diseases and their associated complications is propelling the demand for C-B-D-based therapeutic solutions. The medicinal prowess of C-B-D, a chemical compound primarily found in the sa-tiva strain of canna-bis, is emerging as a game-changer in managing conditions such as anxiety and seizures. As the call for C-B-D for wellness and overall health gains momentum, the market is experiencing an upsurge.

One pivotal catalyst for market expansion is the greater acceptance and utilization of C-B-D-infused products, driven by regulatory approvals. The endorsement of C-B-D by regulatory bodies is fostering an environment conducive to the development and production of an array of C-B-D-infused items. Furthermore, the historical use of canna-bis in pain management, coupled with contemporary scientific findings highlighting the pain-relieving properties of C-B-D and other canna-bis constituents, is further fueling the market’s growth.

The spectrum of medical conditions treated with Canna-bi-diol (C-B-D) continues to broaden, encompassing pain, anxiety, dystonia, Crohn’s disease, Parkinson’s disease, and various other ailments. Consequently, the global embrace of Canna-bi-diol is expanding, positioning it as an increasingly favored therapeutic solution worldwide.

The Diverse Applications of Canna-bi-diol (C-B-D) (3)

Canna-bi-diol (C-B-D) boasts a diverse range of applications, with its versatility extending into the personal care and cosmetic product industry. As a prominent active ingredient, it is making its presence felt in various product categories such as pet supplies, cosmetics, health, and beauty goods. What sets C-B-D apart is its non-psychoactive nature, making it the most commonly used cannon-bi-noid for therapeutic purposes.

The medicinal use of Canna-bi-diol oil is extensive, encompassing treatments for anxiety, depression, stress management, diabetes, pain relief, cancer symptom mitigation, and inflammation reduction. This wide spectrum of applications is reshaping the global market, propelling it towards profitable expansion throughout the forecast period. The increasing adoption of C-B-D-based products for treating a myriad of illnesses is a testament to its growing prominence and efficacy.

As the Canna-bi-diol (C-B-D) market charts a course toward exponential growth, MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) emerges as a notable player poised to capitalize on this burgeoning industry.

With its innovative approach to canna-bi-noid-based therapies and a commitment to research and development, MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is well-positioned to contribute significantly to the evolving landscape of C-B-D and canna-bis-related pharmaceuticals.

Industry enthusiasts would be wise to keep a watchful eye on MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) as it continues to navigate this dynamic and promising market.

Keep reading to see why MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) needs to be at the top of your daily watch-list starting today!

1. Recent IPO

One of the most compelling reasons to start your research on MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is its recent IPO. The company raised a substantial $8.9 million in capital through this public offering. This influx of funds is earmarked for advancing critical toxicology and clinical research efforts, bringing MIRA's revolutionary drug closer to the market. The recent IPO not only signifies market interest but also underscores the company's commitment to achieving accelerated growth and delivering on its groundbreaking promises. (6)

2. Higher Potential for Growth

In general, micro-cap companies have market capitalizations of between $50 million and $300 million. (7) Because micro-cap stocks are significantly smaller than mid-cap or large-cap companies, they have a higher potential to change valuation quickly. (7) As of 10/20/2023, MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) has a market cap of approximately $46.12 million according to MarketWatch.com. (8)

3. Strong Insider Ownership

Remarkably, insiders at MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) exhibit unwavering confidence by owning an impressive 65.44% of the company's shares according to Finviz.com (as of 10/20/23). (9) This high degree of insider ownership serves as a potent indicator of the company's overall health and long-term potential. When key figures within the organization, including executives and essential personnel, hold such a substantial portion of the company's stock, it sends a clear and powerful message to the market. (10)

4. Expansive and Growing Markets

The markets related to anxiety disorders, cognitive impairment, and neuropathic pain are booming. The Canna-bi-diol (C-B-D) market is set to surge by an astonishing 293% by 2030, (2) making it an opportune time to explore MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA). Anxiety disorders, impacting over 40 million U.S. adults, pose a substantial challenge with conventional treatments often falling short. Cognitive impairment is on the rise, with a projected North American Alzheimer's drugs market of about $13 billion by 2030. (11)

5. Innovative Therapeutic Advancements

Positioned at the forefront of pioneering therapeutic solutions, MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is leading the way with its groundbreaking compound, MIRA1a. This revolutionary molecule has the potential to address critical medical needs in areas such as anxiety, cognitive impairment, and neuropathic pain. What sets MIRA1a apart is its unique approach, effectively harmonizing the benefits of tetra-hydro-canna-binol (T-H-C) and canna-bidiol (C-B-D) while selectively targeting canna-bi-noid receptors CB1 and CB2. This strategy unveils a promising avenue for innovative therapies that could transform the landscape of medical treatments. By exploring the potential of MIRA1a, individuals can gain valuable insights into the company's innovative capabilities and the future of pharmaceutical advancements. (11)

6. FDA Approval

If approved by the FDA, MIRA1a could signify a groundbreaking leap in tackling various neuropsychiatric, inflammatory, and neurologic diseases and disorders. As the first prescription MJ drug targeting concerns like anxiety, chronic pain, and appetite suppression, it opens doors to a compelling market opportunity for MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA). With the credibility and safety validations of FDA screening and approval, stakeholders are able to see the potential of MIRA Pharmaceuticals securing a robust market presence. (1)

7. Potential for Game-Changing Solutions

MIRA1a, developed by MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA), presents a pioneering approach with its unique strategy for modulating the endocanna-bi-noid system. This innovative method holds the potential to be a game-changer when it comes to addressing complex medical conditions. Historically, conditions like anxiety disorders, cognitive impairment, and neuropathic pain have provided limited treatment avenues, often leaving patients and healthcare providers in search of innovative alternatives. However, MIRA1a sets itself apart by offering robust anti-anxiety effects without the typical drawbacks of sedation or intoxication. (11)

MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA)
IPO’s on the Nasdaq… (6)

In a significant move poised to shake up the medicinal canna-bis landscape, MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) recently made its debut on the Nasdaq stock exchange. CEO Erez Aminov shared insights into the company’s groundbreaking initiatives as trading commenced under the ticker symbol ‘MIRA.’

Image Source (12)

MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is spearheading transformative developments within the canna-bis industry, particularly with the creation of a synthetic MJ analog. This pioneering molecular entity, crafted using patented technology, has the potential to revolutionize medicinal canna-bis consumption by offering the benefits of T-H-C and C-B-D without their typical adverse effects, which often include paranoia, anxiety, and impaired cognition.

One of the most remarkable aspects of this synthetic compound, as revealed by clinical studies conducted at John Hopkins Medical School, is its multifaceted potential. Notably, it not only mitigates anxiety and chronic pain but also demonstrates a staggering 100% enhancement in cognition based on animal studies.

MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA)’s synthetic T-H-C is strategically positioned for medicinal use and is currently undergoing rigorous evaluation by the FDA. The pharmaceutical-grade version aspires to present a clean, secure, and efficacious alternative for patients seeking canna-bis-based relief, eliminating the impurities and toxicity often associated with plant-based MJ products.

What sets MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA)’s offering apart is its unscheduled status, opening the doors for federal employees and veterans to access its therapeutic benefits. This progressive approach underscores the company’s overarching mission: addressing unmet medical needs, particularly concerning anxiety and cognitive impairment among early-stage dementia patients, while minimizing the occurrence of side effects.

The recent IPO marked a significant financial milestone for MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA), with a total capital raise of $8.9 million. The majority of these funds will be channeled towards expediting toxicology and clinical research processes, propelling the revolutionary drug closer to reaching the market. As the company positions itself at the forefront of canna-bis innovation, industry stakeholders should be keenly watching MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) as it pioneers a path toward a promising future in medicinal canna-bis therapeutics. (6)

Micro-CAP Stocks

Could MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) Have a Higher Potential for Growth? (7)

In general, micro-cap companies have market capitalizations of under $300 million.. (7) Because micro-cap stocks are significantly smaller than mid-cap or large-cap companies, they have a higher potential to change valuation quickly. . (7) As of 10/20/2023, MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) has a market cap of approximately $46.12 million according to MarketWatch.com. (8)

Companies with market caps this small may be overlooked by the public, as they often receive little attention from analysts and institutions. This can provide excellent research opportunities for individuals who are seeking to discover hidden gems. These small and often little-known companies may bring major improvements to existing products and services as well as introduce new products, using innovation to accelerate growth. (15) 

Moreover, MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) has a “low float.”(8) 

Low float stocks have the potential to present significant swings if active market participants take notice,(9)  which makes MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) an attractive watch target for those looking for companies with significant growth potential.

Market participants also typically consider a float of 10-to-20 million shares as a low float. Some larger corporations have very high floats in the billions. (14) 

As of 10/20/2023, MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) has less than 5.2 million shares available in its public float according to MarketWatch.com. (8) 

Companies with a low float frequently have a large portion of their equity held by controlling investors such as directors and employees, which leaves only a tiny percentage of the stock available for public trading. (14) 

In the case of MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA), insiders own over 65% of the company’s shares as of 10/20/2023 according to Finviz.com. (9) 

This high degree of insider ownership serves as a potent indicator of the company’s overall health and long-term potential. When key figures within the organization, including executives and essential personnel, hold such a substantial portion of the company’s stock, it sends a clear and powerful message to the market.(10) 

Overall, MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA), has several positive catalysts, such as its potential for growth and low public float, making it an attractive research option right now.

Keep reading to learn more about MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) and why it deserves to be at the top of your daily watch list.

 

MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA): Revolutionizing Canna-bi-noid Drug Development with Mira 1A… (11)

Image Source (11)

In recent years, the field of pharmaceuticals has witnessed significant advancements, especially in the realm of canna-bi-noid-based medicines. MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) has emerged as a groundbreaking player in this arena, thanks to its pioneering compound, Mira 1A. This innovative molecule is poised to address the central challenges in canna-bi-noid drug development, promising to revolutionize the medical canna-bis industry.

A Revolutionary Compound: Mira 1A (11)

At the heart of MIRA Pharmaceuticals’ mission is Mira 1A, a revolutionary new compound that addresses three fundamental challenges in canna-bi-noid drug development:

Minimizing Negative Effects of T-H-C

One of the primary challenges in utilizing canna-bis for therapeutic purposes is mitigating the negative effects of T-H-C (tetra-hydro-canna-binol), which can include impaired memory, increased appetite, paranoia, and euphoria.

Optimal Combination of T-H-C and C-B-D

Mira 1A aims to harness the therapeutic potentials of both T-H-C and C-B-D (canna-bidiol) effectively. While these two compounds have similar molecular structures, they interact differently with the body's endo-canna-bi-noid system, resulting in unique effects.

Enhancing Beneficial Effects

Mira 1A seeks to enhance the beneficial effects of both T-H-C and C-B-D while minimizing their negative side effects. C-B-D has been shown to help treat anxiety, pain, and seizures, making it a valuable component in canna-bi-noid medicine.

The Birth of Mira 1A (11)

Derived from the canna-bis plant, T-H-C, and C-B-D have been used as medicines for millennia. However, the natural canna-bis plant contains significantly more T-H-C than C-B-D, leading to the potential for unwanted side effects. T-H-C and C-B-D, while structurally similar, have distinct interactions with the endo-canna-bi-noid system, resulting in unique effects.

T-H-C, for instance, can produce euphoria but may also lead to negative mood, impaired memory, and paranoia. On the other hand, C-B-D lacks these negative side effects and can even counteract some of the problems associated with T-H-C. It has demonstrated promise in treating anxiety, pain, and seizures. (11)

Mira 1A bridges the gap between T-H-C and C-B-D by capturing the anti-inflammatory, anti-pain, and anti-anxiety properties of C-B-D while moderating the negative side effects of T-H-C. This innovative compound targets specific binding sites in the body’s endo-canna-bi-noid system, offering the therapeutic potential of MJ within a single, pure molecule. (11)

Key Advantages of Mira 1A (11)

Mira 1A offers several key advantages:

Purity

Mira 1A is pure and free from other canna-bi-noid metabolites, ensuring consistent and controlled dosing.

Potency

It synergizes and enhances the therapeutic potential of T-H-C and C-B-D while avoiding their negative side effects.

Patented

Mira 1A is fully patented as a new chemical entity, securing its uniqueness and innovation in the pharmaceutical landscape.

The Future of Mira 1A (11)

Mira 1A is being developed as the first prescription MJ drug to treat anxiety, chronic pain, and appetite suppression. Physicians and patients can look forward to a pure pharmaceutical solution that comes with the confidence and safety assurances of FDA screening and approval. Image Source (19)

As MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) continues its research and development efforts, the potential of Mira 1A to transform the medical canna-bis industry and provide relief to patients suffering from various ailments appears promising. This innovative compound represents a significant step forward in canna-bi-noid drug development, offering a new path to harness the therapeutic potential of canna-bi-noids while minimizing their drawbacks.

Mira 1A stands as a testament to the innovative spirit of MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA), and the ever-evolving landscape of canna-bi-noid-based medicine. As the pharmaceutical world watches with anticipation, it is clear that Mira 1A has the potential to make a lasting impact on the treatment of chronic pain, anxiety, and appetite suppression. (11)

Unlocking Therapeutic Potential: MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA)’s MIRA1a… (16)

mira pills

In the evolving landscape of pharmaceuticals, MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) has emerged as a promising player, driven by its groundbreaking compound, MIRA1a. This innovative molecule is poised to address the pressing medical needs of anxiety, cognitive impairment, and neuropathic pain with a unique approach that balances the benefits of tetra-hydro-canna-binol (T-H-C) and canna-bidiol (C-B-D), targeting canna-bi-noid receptors CB1 and CB2. MIRA1a offers potent anti-anxiety effects without the drawbacks of sedation or intoxication, making it a potential game-changer in multiple therapeutic markets. Image Source (17)

Anxiety Disorder: A Widespread Challenge (16)

Anxiety disorders affect millions of individuals, with over 40 million adults in the United States alone grappling with various forms of anxiety, including phobias, social anxiety disorder, post-traumatic stress disorder (PTSD), generalized anxiety disorder (GAD), and panic disorder. These conditions manifest as an overwhelming sense of apprehension, often accompanied by physical symptoms like sweating, palpitations, and stress. The toll on the quality of life and overall well-being can be profound.

Current treatments for anxiety disorders include cognitive-behavioral therapy and pharmacological options like SSRIs, SNRIs, and TCAs. However, these treatments are not universally effective and can come with a range of side effects. MIRA1a offers a novel approach by targeting the endo-canna-bi-noid system, potentially providing anti-anxiety effects that are both potent and devoid of the sedation and intoxication often associated with traditional therapies.

Cognitive Impairment: A Growing Concern (16)

Cognitive impairment, encompassing conditions such as Alzheimer’s disease, dementia, mild cognitive impairment (MCI), and related disorders, presents a growing healthcare challenge. Approximately 16 million people in the United States are living with cognitive impairment, and this number is expected to rise as the population ages. Current treatments for cognitive impairment, especially Alzheimer’s disease, are primarily palliative, offering symptom relief but lacking the ability to halt or reverse disease progression.

The North American Alzheimer's drugs market is projected to reach around $13 billion by 2030, highlighting the immense demand for more effective treatments. MIRA1a's potential to target canna-bi-noid receptors CB1 and CB2, with a focus on cognitive function, offers a promising avenue for innovative therapies that could transform the field of cognitive impairment treatment. Image Source (18)

Neuropathic Pain: A Complex Challenge (16)

Neuropathic pain, stemming from dysfunction or damage to the nervous system, poses a complex and often treatment-resistant pain condition. It affects approximately 7-10% of the general population and includes conditions like diabetic peripheral neuropathy, postherpetic neuralgia, and multiple sclerosis-related neuropathy. Neuropathic pain persists even after the initial cause has been addressed, representing a malfunction in nerve signaling.

Current treatments for neuropathic pain involve medications like anticonvulsants and antidepressants, which can have limited effectiveness and unwanted side effects. The opioid crisis has further reduced the reliance on opioids as a treatment option due to their addiction risks.

Pharmaceutical companies are actively seeking targeted and efficient therapies for neuropathic pain, recognizing the immense suffering and morbidity it can cause. MIRA1a’s unique approach to modulating the endo-canna-binoid system holds the potential to address the distinctive challenges posed by neuropathic pain, offering hope to those who have thus far found limited relief.

MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is positioned at the forefront of pharmaceutical innovation with MIRA1a. This revolutionary compound’s ability to enhance the therapeutic potential for anxiety, cognitive impairment, and neuropathic pain through precise targeting of canna-bi-noid receptors CB1 and CB2 is a beacon of hope for patients and healthcare providers alike. As research and development efforts continue, the future appears promising for MIRA1a’s potential to make a lasting impact on these challenging therapeutic markets.

 

Innovative Compound MIRA1a: MIRA Pharmaceuticals is on the cutting edge of pharmaceutical innovation with its revolutionary compound, MIRA1a. This groundbreaking molecule has the potential to address the significant medical needs of individuals dealing with anxiety, cognitive impairment, and neuropathic pain. What sets MIRA1a apart is its unique approach, striking a balance between the therapeutic benefits of T-H-C and C-B-D, targeting canna-bi-noid receptors CB1 and CB2. This innovative compound offers potent anti-anxiety effects without the drawbacks of sedation or intoxication, making it a potential game-changer in multiple therapeutic markets.

Addressing Widespread Challenges: The therapeutic markets for anxiety disorders, cognitive impairment, and neuropathic pain are substantial and growing. Anxiety disorders alone affect over 40 million adults in the United States, representing a widespread challenge with a significant impact on individuals’ quality of life. Current treatments for these conditions often come with limitations and side effects. MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA)’s novel approach, with its potential to target the endo-canna-bi-noid system, could provide more effective and well-tolerated treatment options for patients, meeting a critical need in the healthcare market.

Market Potential and Demand: The market potential for innovative therapies like MIRA1a is substantial. In the case of cognitive impairment, the North American Alzheimer’s drugs market is projected to reach approximately $13 billion by 2030. This highlights the immense demand for more effective treatments in this space. Additionally, neuropathic pain affects a significant portion of the population, and there is a growing need for targeted and efficient therapies. As MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) continues to develop MIRA1a and explore its potential, the company is well-positioned to capitalize on these expanding markets and potentially transform the landscape of treatment options. (16)

SUBSCRIBE TO OUR NEWSLETTER FOR MUST READ REPORTS & NEWS.

Getting the Right News Before Everyone Else Does, is FREE…

Terms | Privacy Policy Message and data rates may apply.
Reply STOP keyword to be opted out of the program. Reply Help for Help. We will never sell or share to third parties. For informational purposes only.

Meet the MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA)
Leadership Team (16)

Discover the key members of MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) who are driving innovation and growth in the pharmaceutical industry:

Image Source (20)
Erez Aminov

Chief Executive Officer

Erez Aminov boasts over 18 years of expertise in finance and investment. He serves as the CEO of MIRA Pharmaceuticals Inc. and is the founder of Locate Venture Corp. Erez also holds the role of Director of Business Development for Tyna Pharmaceuticals and Telomir Pharmaceuticals, where he leverages his vast knowledge to fuel growth and success. His responsibilities at TYNA Pharmaceuticals include identifying and pursuing new business opportunities for the clinical-stage biopharmaceutical company. Similarly, as Director of Business Development for Telomir Pharmaceuticals, Erez is responsible for identifying and pursuing new business opportunities in the biotechnology sector. (20)

Erez Aminov holds a B.A. in Accounting from Touro University in New York and also serves as a senior consultant to MyMD Pharmaceuticals (NASDAQ), providing valuable insights and guidance to support the company’s growth and success. Beyond his professional endeavors, Erez is a dedicated family man and a passionate traveler who enjoys exploring new cultures and cuisines. He is also actively involved in philanthropic efforts within his community. (20)

Dr. Adam Kaplin brings a wealth of experience to MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA). Prior to joining the company, he held various positions at John Hopkins University, including Principal Neuro-Psychiatric Consultant to the Johns Hopkins Multiple Sclerosis Center of Excellence and Director of the Johns Hopkins Ketamine Clinic and the Departments of Psychiatry & Neurology at Johns Hopkins University School of Medicine. Dr. Kaplin is currently an Adjunct Faculty at George Mason University Department of Global and Community Health. (20)

Additionally, Dr. Kaplin is a Co-Founder of several healthcare-related startups, including REWARD Pathways Inc., focusing on addiction treatment development, and Hollinger Kaplin Benjamin & Bond, an eHealth software development company. His research primarily centers on the biological basis of immune-mediated depression and cognitive impairment, with a focus on multiple sclerosis as the model. Dr. Kaplin has authored numerous research papers and review articles, and he received his B.S. in Biology from Yale University and his M.D. and Ph.D. from the Johns Hopkins University School of Medicine. (20)

Image Source (20)
Adam Kaplin, MD, PhD

Cofounder, President, and Chief Scientific Officer

Image Source (20)
Michelle Yanez, MBA

Chief Financial Officer, Secretary, and Treasurer

Michelle Yanez has been serving as the Chief Financial Officer at MIRA Pharmaceuticals, Inc. since April 2023, previously holding the position of Corporate Controller since May 2022. She brings over 25 years of experience in the biotech, pharmaceutical, and life science sectors. Her background includes various financial responsibilities in complex and regulated markets. Michelle also serves as a part-time Corporate Controller at Telomir Pharmaceuticals, Inc. Her extensive experience extends to corporate governance through her involvement with corporate boards, including audit and finance committees. (20)

Prior to joining MIRA Pharmaceuticals, Ms. Yanez held various positions in BioDelivery Sciences International, Inc. (NASDAQ:BDSI), including Director of Financial Reporting. She has also served as an independent director of Inhibitor Therapeutics, Inc. (OTCQB: INTI), a publicly traded pharmaceutical development company focused on therapeutics for certain cancers and non-cancerous proliferation disorders, since December 2022. Michelle is a member of the Institute of Management Accountants and the SEC Professionals Group. She earned her MBA from Rutgers School of Business, Cum Laude. (20)

Christos Nicholoudis joined MIRA Pharmaceuticals as General Counsel in March 2023. His background includes serving as a public defender for the 12th Judicial Circuit for the State of Florida from 2019 to 2022, providing him with valuable courtroom and trial experience. Christos has also represented clients dealing with substance abuse, offering a unique perspective and commitment to Mira’s mission. (20)

 

After his work with the State, he started his practice in February 2022, handling various legal matters, including contracts, personal injury, real estate, wills, trusts, estates, and criminal law. Before his legal career, Mr. Nicholoudis was involved in the hospitality industry, owning and operating a restaurant in Bradenton, Florida, and working on developing a 5-star hotel in Mykonos, Greece, with his family. (20)

 

He is a graduate of Cornell University’s School of Hotel Administration and received his J.D. from Stetson College of Law. Christos is admitted to the bar in New York, Florida, Texas, and Washington D.C. He is multilingual, speaking English, Greek, Russian, and Hebrew, and is actively involved in community theater as a classically trained tenor. (20)

Image Source (20)
Christos Nicholoudis, Esq.

General Counsel

These dedicated professionals form the core leadership team at MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA), driving innovation and growth in the pharmaceutical industry through their expertise and commitment to the company’s mission and vision. (20)

Meet the Little-Known Disruptor Eyeing the 293+% Growth of a Potential $59 Billion Market… (1) (3) 

See what FDA approval could mean for little-known MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA).
Keep reading to see why MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) needs to be at the top of your daily watch-list starting today!​

1. Recent IPO

One of the most compelling reasons to start your research on MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is its recent IPO. The company raised a substantial $8.9 million in capital through this public offering. This influx of funds is earmarked for advancing critical toxicology and clinical research efforts, bringing MIRA's revolutionary drug closer to the market. The recent IPO not only signifies market interest but also underscores the company's commitment to achieving accelerated growth and delivering on its groundbreaking promises. (6)

2. Higher Potential for Growth

In general, micro-cap companies have market capitalizations of between $50 million and $300 million. (7) Because micro-cap stocks are significantly smaller than mid-cap or large-cap companies, they have a higher potential to change valuation quickly. (7) As of 10/20/2023, MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) has a market cap of approximately $46.12 million according to MarketWatch.com. (8)

3. Strong Insider Ownership

Remarkably, insiders at MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) exhibit unwavering confidence by owning an impressive 65.44% of the company's shares according to Finviz.com (as of 10/20/23). (9) This high degree of insider ownership serves as a potent indicator of the company's overall health and long-term potential. When key figures within the organization, including executives and essential personnel, hold such a substantial portion of the company's stock, it sends a clear and powerful message to the market. (10)

4. Expansive and Growing Markets

The markets related to anxiety disorders, cognitive impairment, and neuropathic pain are booming. The Canna-bi-diol (C-B-D) market is set to surge by an astonishing 280% by 2030, (2) making it an opportune time to explore MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA). Anxiety disorders, impacting over 40 million U.S. adults, pose a substantial challenge with conventional treatments often falling short. Cognitive impairment is on the rise, with a projected North American Alzheimer's drugs market of about $13 billion by 2030. (11)

5. Innovative Therapeutic Advancements

Positioned at the forefront of pioneering therapeutic solutions, MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is leading the way with its groundbreaking compound, MIRA1a. This revolutionary molecule has the potential to address critical medical needs in areas such as anxiety, cognitive impairment, and neuropathic pain. What sets MIRA1a apart is its unique approach, effectively harmonizing the benefits of tetra-hydro-canna-binol (T-H-C) and canna-bidiol (C-B-D) while selectively targeting canna-bi-noid receptors CB1 and CB2. This strategy unveils a promising avenue for innovative therapies that could transform the landscape of medical treatments. By exploring the potential of MIRA1a, individuals can gain valuable insights into the company's innovative capabilities and the future of pharmaceutical advancements. (11)

6. FDA Approval

If approved by the FDA, MIRA1a could signify a groundbreaking leap in tackling various neuropsychiatric, inflammatory, and neurologic diseases and disorders. As the first prescription MJ drug targeting concerns like anxiety, chronic pain, and appetite suppression, it opens doors to a compelling market opportunity for MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA). With the credibility and safety validations of FDA screening and approval, stakeholders are able to see the potential of MIRA Pharmaceuticals securing a robust market presence. (1)

7. Potential for Game-Changing Solutions

MIRA1a, developed by MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA), presents a pioneering approach with its unique strategy for modulating the endocanna-bi-noid system. This innovative method holds the potential to be a game-changer when it comes to addressing complex medical conditions. Historically, conditions like anxiety disorders, cognitive impairment, and neuropathic pain have provided limited treatment avenues, often leaving patients and healthcare providers in search of innovative alternatives. However, MIRA1a sets itself apart by offering robust anti-anxiety effects without the typical drawbacks of sedation or intoxication. (11)

Source 1: https://finance.yahoo.com/news/mira-pharmaceuticals-shows-prescription-pill-123000998.html

Source 2: https://www.precedenceresearch.com/cbd-consumer-health-market

Source 3: https://tinyurl.com/y6saruu3

Source 4: https://www.barchart.com/stocks/quotes/MIRA/price-history/historical

Source 5: https://schrts.co/ZyaQGvYZ

Source 6: https://finance.yahoo.com/news/mira-pharmaceuticals-debuts-nasdaq-plans-184022205.html

Source 7: https://www.carboncollective.co/sustainable-investing/microcap-stock

Source 8: https://www.marketwatch.com/investing/stock/mira?mod=search_symbol

Source 9: https://finviz.com/quote.ashx?t=MIRA&p=d

Source 10: https://www.investopedia.com/articles/stocks/05/042605.asp

Source 11: https://d1io3yog0oux5.cloudfront.net/_22b1572e94e8eeeb9b74ab69bc259dc1/mira1a/db/873/7909/video_mp4/whatismira.mp4

Source 12: https://media.bizj.us/view/img/12572687/mira-opening-bell-ceremony*1600xx4290-2413-0-126.jpg

Source 13: https://www.tomorrowmakers.com/sites/default/files/2023-07/micro-cap%20stocks.jpg

Source 14: https://www.sofi.com/learn/content/understanding-low-float-stocks/

Source 15: https://www.globexmarkets.com/financial-terms/n/nano-cap-stock.html

Source 16: https://www.mirapharmaceuticals.com/mira1a/research-publications

Source 17: https://tinyurl.com/yj8jekct

Source 18: https://media-cldnry.s-nbcnews.com/image/upload/t_fit-1500w,f_auto,q_auto:best/mpx/2704722219/2021_06/1623153063458_tdy_news_7a_gosk_fda_alzheimers_210608_1920x1080.jpg

Source 19: https://mdic.org/wp-content/uploads/2020/06/FDA-Logo.jpg

Source 20: https://www.mirapharmaceuticals.com/about-us/leadership

GET RED-HOT NEWS DELIVERED RIGHT TO YOUR INBOX:

Getting the Right News Before Everyone Else Does, is FREE…

Terms | Privacy Policy Message and data rates may apply.
Reply STOP keyword to be opted out of the program. Reply Help for Help. We will never sell or share to third parties. For informational purposes only.